US Capitol Capsule: Record approvals, new legislation: Big things happening in rare diseases
This article was originally published in Scrip
With approvals of drugs in the US to treat orphan conditions hitting an all-time high in 2014, new legislative efforts with new incentives that have the potential to be enacted in 2015 and science moving at an unprecedented pace because of new molecular research capabilities, big things are happening in rare diseases, officials declared at a 27 February conference hosted by the National Institutes of Health (NIH).
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.